Oncology

A study published in Health Affairs shows that lung and colorectal cancer mortality was higher among veterans who were unhoused compared with those who were housed and higher yet in those who lost housing after they received a diagnosis.

The drugmaker is spending $15 million over a three-year period to address cancer care disparities in breast and prostate cancer.

The Oncologic Drugs Advisory Committee will meet on March 15, 2024, to review overall survival data for Abecma in earlier lines of treatment in relapsed or refractory multiple myeloma.

Leaders at City of Hope, a cancer research and care center in Los Angeles, forecast that in 2024 more people will benefit from cancer breakthroughs.

Bristol Myers Squibb is seeking approval of Breyanzi, a CD19-directed CAR T-cell therapy, to treat patients with follicular lymphoma and mantle cell lymphoma.

The FDA orders new warnings for CAR-T cell therapies due to reports of T-cell malignancies, including fatal cases, applying to BCMA- and CD19-directed genetically modified autologous T-cell immunotherapies.

Adherent patients accessed services only slightly more.

Balversa targets FGFR3 genetic alterations and is approved as a second-line treatment for in adult patients with metastatic urothelial carcinoma.

Adstiladrin delivers a gene that encodes for the interferon alpha-2b protein, and it provides an option for those at high risk of recurrence and metastatic bladder cancer.

Researchers developed a new multi-cancer blood screening test to detect early-stage cancers and found it had a high level of accuracy.

Tivdak was granted accelerated approval in September 2021 to treat patients with recurrent or metastatic cervical cancer. The goal date for full approval is May 9, 2024.

The FDA cited issues with a third-party manufacturing company. Zolbetuximab is being reviewed to treat patients with stomach cancer.

Recent research finds that the prices of cancer drugs are rising, but the factors that contribute to the increases are difficult to pinpoint.

Results point to the benefit of adding Darzalex (daratumumab) to Velcade-Revlimid-dexamethasone triplet therpay, although serious side effects seem be slightly more common when Darzalex is added.

A combination of navitoclax and Jakafi (ruxolitinib) achieved spleen volume reduction, although adverse events led to some dose modifications and treatment interruptions.

Loqtorzi has a wholesale acquisition cost of $8,892.03 per single-use vial.

Additionally, the FDA has approved Avzivi — the fifth biosimilar that references the cancer drug Avastin.

Welireg is now also indicated for patients whose renal cell carcinoma has progressed after treatment with PD-1 or PD-L1 inhibitor and a TKI therapy.

The FDA has set a target date of June 12, 2024, for tarlatamab to treat adult patients with advanced small cell lung cancer. If approved, it would be the first bispecific antibody for a solid tumor.

Augtyro, approved last month, launched with a month wholesale acquisition $29,000 for patients with ROS1-positive non-small cell lung cancer.

Shortages are growing because of disruption caused natural disasters and ingredient supply issues, as well as increased demand for certain drugs.

Jaypirca is also approved to treat mantle cell lymphoma. It has a list price of $21,000 for a 30-day supply.

Ogsiveo will be available within five to 10 business days to treat patients with desmoid tumors. It will launch with a price of $29,000 for a 30-day supply.

Janssen is seeking approval for use after Tagrisso in patients with metastatic non-small cell lung cancer.

A regulatory decision will not be made by the Prescription Drug User Fee Act (PDUFA) target action date of Dec. 16, 2023.